New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07229313
Summary
This is the first study in people to test a new cancer drug called KIVU-107. The main goal is to find a safe dose and see how well the body handles it. It is for adults with advanced solid tumors that have spread or cannot be removed by surgery and have stopped responding to available treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kivu Trial Site
RECRUITINGSydney, New South Wales, Australia
-
Kivu Trial Site
RECRUITINGBrisbane, Queensland, Australia
-
Kivu Trial Site
RECRUITINGAdelaide, South Australia, Australia
-
Kivu Trial Site
RECRUITINGGeelong, Victoria, Australia
Conditions
Explore the condition pages connected to this study.